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Table
Association betweenMPA total serum trough levels and toxicity and efﬁcacy
outcomes
1A) Toxicity outcome: Time-dependent Cox regression
Outcome N HR (95% CI) P-value
Time to neutrophils
 0.5 k/mcL
61 1.45 (0.65 - 3.25) 0.36
Time to platelets
 20 k/mcL
61 1.88 (0.82 - 4.30) 0.14
Time to TPN cessation 61 0.56 (0.20 - 1.58) 0.28
Time to CMV viremia 31 1.71 (0.38 - 7.59) 0.48
IB) Efﬁcacy outcome: Cumulative incidence of aGVHD by day 100
Outcome N Cumulative incidence
(95% CI)
P-value
aGVHD II-IV
Trough < 0.5 mcg/mL 15 0.67 (0.41 - 0.92) 0.29
Trough  0.5 mcg/mL 57 0.57(0.44 - 0.71)
aGVHD III-IV
Trough < 0.5 mcg/mL 15 0.27 (0.03 - 0.50) 0.12
Trough < 0.5 mcg/mL 57 0.11 (0.03 - 0.19)
Abstracts / Biol Blood Marrow Transplant 19 (2013) S370eS380 S377in 16% of LZ patients vs. 7% of controls. Forty-six percent of
LZ patients vs. 13% of controls failed to achieve platelet
engraftment. The cumulative incidence of engraftment of
neutrophils plus platelets (using death without engraftment
as the competing risk) was lower in the LZ group (54%) vs.
the control group (83%) (P ¼ .005). Day 100 survival rates
were 58% for the LZ group vs. 92% for controls. Survival
probability is shown in Figure 1.
Conclusions: LZ does not signiﬁcantly affect time to
neutrophil engraftment, but does appear to prolong time to
platelet engraftment when compared to patients who did
not receive LZ. LZ should be used cautiously early after stem
cell transplantation.
Figure 1. Overall Survival
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Background: Mycophenolate mofetil (MMF) is frequently
combined with cyclosporine-A as immunosuppression in
unrelated donor CBT. Recent evidence suggests that thera-
peutic drug monitoring of mycophenolic acid (MPA), the
active metabolite of MMF, is advisable based on intra- and
inter-patient variability of MMF pharmacokinetics (PK).
Moreover, an increased incidence of acute graft-versus-host
disease (aGVHD) has been associated with low unbound
MPA AUCs in adult allograft recipients. This is highly rele-
vant in CBT as aGVHD is a leading cause of transplant-
related mortality. However, as AUCs are cumbersome,
a limited PK parameter such as MPA troughs would be ideal.
Also, the toxicity associated with MPA trough levels is not
established.
Methods: We evaluated the association between serial MPA
total serum trough levels in weeks 1-6 and transplant
outcomes in pediatric and adult double-unit CB recipients
transplanted 8/2009 to 6/2012 for hematologic malignancies
with 4-6/6 HLA-A,B antigen, DRB1 allele matched CB grafts.
To evaluate the association between trough levels andoutcomes, the trough levels were dichotomized into < 2
mcg/mL and  2 mcg/mL for toxicity (delayed engraftment,
gastrointestinal toxicity, viral infection), and < 0.5 mcg/mL
and  0.5 mcg/mL for efﬁcacy (aGVHD prevention) at each
time point.
Results: Seventy-four patients had MPA total serum trough
levels drawn weekly for 6 weeks. Sixty-one (82%) received
myeloablative (MA) conditioning and 31 (42%) were CMV
seropositive. Median trough levels by week were 0.9, 0.9,
0.6, 0.7, 0.9, and 1.3 mcg/mL. The change in trough levels
over time did not reach signiﬁcance (P ¼ .07). Recipients
of MA conditioning had lower MPA troughs than those
who received non-myeloablative conditioning (P ¼ .03). By
time-dependent Cox regression analysis, there was no
association between trough levels and toxicity as
measured by time to neutrophil and platelet recovery or
duration of total parenteral nutrition (TPN) in myeloa-
blative CBT recipients, or time to viremia in CMV sero-
positive patients (Table 1A). In a competing risk 2-week
landmark analysis, while differences between groups did
not reach signiﬁcance, it was notable that the incidence of
severe (grade III-IV) aGVHD was more than doubled in
those with a mean week 1 and 2 trough level < 0.5 mcg/
mL (Table 1B).
Conclusions: Analysis of this limited patient population
suggests that while MPA total serum trough levels appear to
have little effect on toxicity outcomes, the early post-trans-
plant (week 1-2) mean levels could be associated with the
risk of severe (grade III-IV) aGVHD. Further investigation in
a larger patient series is warranted.548
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Table
Demographics
N 88
Age in years (range) 6  5.8* (0.67-18)
Male 63%
Donor Source
Bone Marrow 44
Peripheral Stem Cells 43
Umbilical Cord Blood 1
Stem Cell Dose (CD34 x106/kg
body weight)
7.94  6.45* (0.85-33)
Type of Transplantation
Autologous 32
Allogeneic 56
GVHD Prophylaxis
Cyclosporine and Methotrexate 32
Tacrolimus and Methotrexate 9
Other 11
OUTCOMES
PO ACV in mg/kg/dose (range) 9.8  3.5* (2.4-28)
PO ACV in mg/dose (range) 200  105* (100-400)
Duration of PO ACV in days (range) 345  154*(7-1337)
Number of VZV Reactivations 1
Time from Transplantation to VZV
Reactivation (range)
498 days
Deaths 3 (relapsed)
1 (cardiac arrest)
Deaths due to VZV 0
Abstracts / Biol Blood Marrow Transplant 19 (2013) S370eS380S378Background: Guidelines recommend anti-mold prophylaxis
in HSCT patients deemed high-risk for IFI; this has led to
long-term use of voriconazole following allogeneic HSCT in
patients that remain immunocompromised. Voriconazole
has three ﬂuoride atoms and has been associated with
periostitis, exostoses, and ﬂuoride toxicity in patients taking
voriconazole following solid organ transplant, HSCT and
leukemia therapy.
Objectives: To describe the incidence of ﬂuoride toxicity in
allogeneic HSCT patients taking voriconazole that had
a ﬂuoride level measured, identify when a ﬂuoride level was
measured due to symptomatic ﬂuoride toxicity in relation to
voriconazole initiation, and describe the clinical presentation
and outcomes of patients with ﬂuoride toxicity in HSCT
patients.
Methods: Retrospective review of all adult allogeneic HSCT
patients at Mayo Clinic Rochester between 1/1/09 e 7/31/12.
Fluoride assays were conducted with an ion selective elec-
trode (normal range 0 e 4 mmol/L).
Results: 292 patients received an allogeneic HSCT between
1/1/09 e 7/31/12. Patients were excluded if they did not
consent to research (n¼4), were treated by the pediatric
service (n¼7), or did not receive voriconazole formore than 7
days (n¼38). The median duration of voriconazole was 167
days (range 7e1321). Of 243 patients included, 32 presented
with musculoskeletal pain and had a ﬂuoride assay. In 31
patients with ﬂuoride measured while on voriconazole, 29
(93.5%) had elevated ﬂuoride levels; 1 patient had a normal
ﬂuoride level measured 1 month after voriconazole discon-
tinuation due to pain. The median ﬂuoride level was 10.5
mmol/L (range 2-24.7). The median time to measurement of
ﬂuoride was 113 days following voriconazole initiation
(range 28e 692). Of the 29 patients with an elevated ﬂuoride
level, pain improved in 17 patients following voriconazole
discontinuation; 2 patients did not have improvement after
holding voriconazole for 1 week and resumed voriconazole.
Four patients had repeat ﬂuoride measurement and subse-
quently discontinued voriconazole because of pain; pain
improved in 2 of those patients, did not improve in 1 patient
and 1 patient was not assessed. Six patients continued vor-
iconazole; pain resolved in 4 of those patients, was not
assessed in 1 patient and persisted in 1 patient with recur-
rent leukemia. Eight patients (27.6%) with elevated ﬂuoride
levels had an estimated glomerular ﬁltration rate < 50 mL/
min.
Conclusions: Of 243 consecutive allogeneic HSCT patients
receiving voriconazole for more than 7 days, the devel-
opment of musculoskeletal pain in 32 (13.2%) patients led
to ﬂuoride assessment; 29 patients (93.5%) with ﬂuoride
levels measured while on voriconazole had elevated
levels. Fluoride toxicity is an adverse effect of vor-
iconazole that should be considered in patients present-
ing with pain and is often reversible following drug
discontinuation.549
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tive in lowering the incidence of Varicella zoster virus (VZV)
reactivation and infections during the ﬁrst year post-trans-
plant in adult hematopoietic stem cell transplantation
(HSCT) patients. Such data are lacking in the pediatric pop-
ulation. The objective of this study was to determine the
effectiveness of low-dose acyclovir prophylaxis in preventing
VZV reactivations and infections in the pediatric HSCT
patients.
Methods Medical records of VZV seropositive patients,
< 18 years of age who received a HSCT between January
2000 and April 2010 were retrospectively reviewed for:
demographics, pre-transplant serology for herpes simplex
virus, VZV and cytomegalovirus, acyclovir (ACV) dosing
both intravenous (IV) and oral (PO), duration of acyclovir
prophylaxis, incidence of reactivation, time to reac-
tivation, age at reactivation, acyclovir prophylaxis status at
the time of reactivation, severity of zoster infection,
duration of follow-up, graft versus host disease (GVHD)
prophylaxis, incidence of GVHD, treatment of acute or
chronic GVHD, deaths, cause of death, and any adverse
effects attributed to acyclovir. Data was analyzed using
descriptive statistics.
Results:Conclusion: ACV at a median dose of 20 mg/kg/day twice
daily was successful in preventing reactivations of VZV in 99
% of pediatric HSCT patients. The median duration of oral
ACV prophylaxis in these patients was 345 days. Reac-
tivation was detected by a qualitative polymerase chain
reaction test positive for the viral DNA in a superﬁcial tissue
sample. Repeat test conducted three weeks later was
negative. The patient was not on ACV at the time of reac-
tivation, did not require treatment for VZV infection, but
was started on valacylovir prophylaxis. According to the
guidelines for preventing infectious complications among
HSCT recipients, the recommended oral ACV dose for VZV
prophylaxis is 60-80 mg/kg/day in two to three divided
doses for children <40 kg body weight and 800 mg of oral
ACV twice daily for children >40 kg body weight. At a dose
